Programme data have reported, for example, higher mean weight loss at 72 weeks with a GIP/GLP-1 regimen than with some GLP-1-only arms at different time pointscontext, population, and rescue/adherence rules all matter
The Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists as Novel Diabetes Drugs Are Mediated via the Suppression of miR-203a-3p and miR-429 Expression
Like the heart benefits, these benefits may be due to weight loss rather than the medication
Understanding the whole patient prior to receiving transplant and cellular therapy: Real-world data on patients financial toxicity prior to receiving treatment Miranda Kapfhammer 1 , Rachel Cusatis 1 , Deborah Mattila 2 , Sarah Smith 2 1 Medical College of Wisconsin, Milwaukee, USA, 2 National Marrow Donor Program (NMDP), Minneapolis, USA Aims Cellular therapy (CT) recipients are at high risk for financial toxicity (FT) given the frequent need for temporary re-location, loss of income for patients and caregivers in addition to the expected medical expenses of cancer care
Seek urgent assessment via NHS 111, eye casualty/A&E, or your GP if you experience: Sudden vision loss or significant deterioration in either eye Floaters (new dark spots or strings drifting through your vision), especially if numerous or increasing Flashes of light in your peripheral vision A curtain or shadow moving across your visual field Distorted vision where straight lines appear wavy or bent Difficulty reading or recognising faces that develops rapidly Blurred vision that doesn't improve with blinking or resting your eyes Eye pain with vision changes or a red, painful eye These symptoms may indicate complications such as vitreous haemorrhage (bleeding into the gel-filled centre of the eye), retinal detachment , or diabetic macular oedema (swelling of the central retina)
